Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Theranos Founder Receives 2-Year Ban From Owning Blood-Testing Lab

XTALKS VITALS NEWS

Elizabeth Holmes

Even amid the growing problems with the CMS and the company’s decision to void thousands of test results from 2014 to 2015, Holmes remained a strong defender of her company and its technology.

Tweetables from this article:

Tweet: CMS has suspended Theranos lab’s ability to bill Medicare and Medicaid  http://ctt.ec/beIQV+CMS has suspended Theranos lab’s ability to bill Medicare and Medicaid.

Tweet: Theranos’ Edison device was predicted to be innovation in blood testing http://ctt.ec/a6s2k+Theranos’ Edison device was predicted to be a major innovation in the blood testing industry.

Share this!

July 11, 2016 | by Sarah Massey, M.Sc.

The Centers for Medicare & Medicaid Services (CMS) has officially banned Theranos founder Elizabeth Holmes from owning or operating a blood testing laboratory, for a minimum two-year period. The federal health regulator has also slammed the company’s Newark, California facility with multiple penalties, including revoking the lab’s Clinical Laboratory Improvement Amendments (CLIA) certificate.

Last fall, the CMS identified multiple violations of proper laboratory practices during a routine inspection of the Newark facility. The severity of the violations prompted the CMS to take serious corrective actions.

Theranos and Holmes have fallen dramatically since promising an inexpensive, rapid and less-invasive blood testing device. Even amid the growing problems with the CMS and the company’s decision to void thousands of test results from 2014 to 2015, Holmes remained a strong defender of her company and its technology.

In addition to a monetary fine, the CMS has also suspended the Newark lab’s ability to bill Medicare and Medicaid for any hematology or laboratory services. Theranos plans to continue offering its blood testing services out of its Arizona-based laboratory.

“We accept full responsibility for the issues at our laboratory in Newark, California, and have already worked to undertake comprehensive remedial actions,” said Holmes. “Those actions include shutting down and subsequently rebuilding the Newark lab from the ground up, rebuilding quality systems, adding highly experienced leadership, personnel and experts, and implementing enhanced quality and training procedures.”



Theranos’ Edison device was predicted to be a major innovation in the blood testing industry. Using a fingerprick to collect a small amount of blood to fill the company’s proprietary “nanotainers”, the test is significantly less-invasive compared to traditional blood-draws using an intravenous needle.

In October of 2015, the Wall Street Journal reported that the company didn’t use the Edison device as often as they claimed, suggesting the technology could be less accurate than previously thought. Instead, Theranos was using traditional diagnostic devices sourced from companies like Siemens.

As Theranos just lost its partnership with Walgreens – forcing the company to close all 40 of its blood testing centers in Arizona – it’s unclear what effect the additional sanctions issued by the CMS will mean for the future of the company. “While we are disappointed by CMS’ decision, we take these matters very seriously and are committed to fully resolving all outstanding issues with CMS and to demonstrating our dedication to the highest standards of quality and compliance,” Holmes continued.


Keywords:  Theranos, Blood Test, Medicare


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.